Legend Biotech Corporation American Depositary Shares (LEGN)
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its growing sales is its superior efficacy compared to Elrexfio, Abecma, and Tecvayli.
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript
Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang - President of Research & Development Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Terence Flynn - Morgan Stanley, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division James Shin - Deutsche Bank AG, Research Division Justin Zelin - BTIG, LLC, Research Division Katherine Degen Ashwani Verma - UBS Investment Bank, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's Third Quarter 2025 Earnings Call.
Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Alan S. Bash - President of CARVYKTI® Caroline LeCates Paul - Associate Director of Investor Relations Jessie Yeung - Interim CFO, Principal Financial Officer & Principal Accounting Officer Mythili Koneru - Chief Medical Officer Ying Huang - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division James John Shin - Deutsche Bank AG, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Leonid Timashev - RBC Capital Markets, Research Division Mitchell Swaroop Kapoor - H.C.
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
What Makes Legend Biotech (LEGN) a New Buy Stock
Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim CFO Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Jon Miller - Evercore Hang Hu - Barclays Yaron Werber - TD Cowen Jessica Fye - JPMorgan Ziyi Chen - Goldman Sachs Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Mitchell Kapoor - H.C. Wainright James Shin - DB Jeet Mukherjee - BTIG Ash Verma - UBS George Farmer - Scotiabank Sean McCutcheon - Raymond James Rick Bienkowski - Cantor Fitzgerald Prem Lachman - Maximus Capital Operator Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call.
Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rates, and strong liquidity stance with $1.2B in cash, ensuring funding into 2026, and low dilution risk.
Legend Biotech: The Story Brightens
Legend Biotech's Carvykti, a CAR-T therapy, has shown significant sales growth since being launched in 2022. The company has some $1.2 billion in cash on its balance sheet and losses are projected to fall dramatically in coming years as revenues soar. Analyst firms are quite optimistic on Legend, with nine analyst firms issuing Buy ratings since Q3 numbers were released with price targets between $73-$94 a share.
